Buffington Mohr McNeal Has $4.74 Million Holdings in Johnson & Johnson (JNJ)

Buffington Mohr McNeal decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,457 shares of the company’s stock after selling 1,030 shares during the period. Johnson & Johnson accounts for 1.8% of Buffington Mohr McNeal’s portfolio, making the stock its 17th largest position. Buffington Mohr McNeal’s holdings in Johnson & Johnson were worth $4,744,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Harding Loevner LP bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares in the last quarter. IHT Wealth Management LLC increased its position in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. 65.71% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently weighed in on JNJ. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a research report on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Citigroup raised their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $145.94.

Shares of Johnson & Johnson (JNJ) opened at $146.92 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $148.32. The company has a market cap of $394,700.00, a P/E ratio of 25.51, a price-to-earnings-growth ratio of 2.77 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.68 EPS. equities analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.29%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

WARNING: This story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://weekherald.com/2018/01/19/buffington-mohr-mcneal-has-4-74-million-holdings-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply